PALI Palisade Bio, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PALI
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.2B
- Employees
- 14
- List Date
- 2021-04-28
- CIK
- 0001357459
- Next Earnings
- 2026-11-09
- EPS Forecast
- ($0.06) (7 est.)
- Headquarters
- Carlsbad, CA
- Homepage
- https://www.palisadebio.com
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -20.53% | -24.08% | 3.56% | -26.88% | -40.40% | -21.67% |
| Feb | -- | -25.20% | -20.30% | -31.47% | -36.48% | 9.94% | -20.70% |
| Mar | -- | 13.73% | 62.21% | -2.18% | -17.74% | -3.31% | 10.54% |
| Apr | -25.76% | -25.00% | -29.65% | 3.02% | 15.87% | 6.38% | -9.19% |
| May | -42.01% | -28.80% | -20.48% | -31.92% | -4.94% | 6.53% | -20.27% |
| Jun | 2.78% | -21.26% | 18.06% | -4.26% | -10.51% | 0.48% | -2.45% |
| Jul | -25.45% | -3.13% | 31.40% | -8.84% | 42.64% | -5.01% | 5.27% |
| Aug | -4.42% | -57.94% | -67.84% | -3.29% | -33.09% | 0.52% | -27.68% |
| Sep | -0.75% | -30.77% | -12.08% | -4.05% | 29.86% | -31.12% | -8.15% |
| Oct | 10.04% | -6.76% | -3.31% | -21.16% | 58.02% | -13.99%* | 3.81% |
| Nov | -14.65% | -15.89% | 13.64% | -11.19% | 5.50% | -- | -4.52% |
| Dec | -34.67% | 35.06% | -2.50% | -31.25% | 25.67% | -- | -1.54% |
| Total | -80.80% | -91.51% | -74.20% | -81.02% | -2.21% | -59.19% | -64.82% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.43
SMA 50: $1.73
SMA 200: $1.87
Current: $1.23
EMA 12: $1.39
EMA 26: $1.50
MACD: -0.1058 | Signal: -0.0037
BEARISH
ADX (14): 34.20
TREND
+DI: 11.97
−DI: 34.42
Momentum Oscillators
RSI (14): 33.14
NEUTRAL
Stoch %K: 9.58
Stoch %D: 16.61
Williams %R: -95.24
Volume & Volatility
BB Upper: $1.60
BB Lower: $1.27
OVERSOLD
OBV: 195,339,252
Vol SMA 20: 2,158,857
Vol ROC: 8.36%
ATR: $0.11
True Range: $0.14
HV 20: 76.8%
HV 30: 87.5%
HV 60: 77.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (confidence level: 6/10)
Key Drivers and Primary Risks:
- Technical analysis suggests a neutral trend, with short-term momentum indicating a potential rebound.
- News sentiment is positive, but recent headlines do not strongly support or contradict technical signals.
- Risk metrics indicate high volatility, which may impact the stock's performance.
Investment Thesis: PALI's current price level and technical indicators suggest a consolidation phase. The positive news sentiment and recent market trends may lead to a rebound in the short-term. However, the stock's high volatility and lack of strong catalysts mean that investors should approach with caution.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (1-4 weeks), Medium-term: BEARISH (1-3 months), Long-term: BEARISH (3-12 months)
Support/Resistance Levels:
- Key price levels from moving averages:
- SMA 20: $2.07
- EMA 12: $2.04
- Technical patterns suggest support at $2.03 and resistance at $2.15
Momentum Signals:
- RSI interpretation: 53.15 (neutral)
- MACD signal: Bullish, indicating a potential rebound
- Bollinger Bands position: Neutral, with the price touching the middle band
Volume Analysis:
- Volume SMA 20: 1569041.12
- On-Balance Volume (OBV): 213616375.17
- Volume Rate of Change: 63.92%
News & Sentiment Analysis
Recent Headlines Summary: Positive news sentiment dominates, with headlines focused on company updates and investor conferences.
Sentiment Assessment: POSITIVE
Catalyst Identification: Upcoming investor conferences and potential product updates may impact the stock's performance.
Market Narrative: The recent positive news sentiment aligns with the technical indicators' neutral trend, suggesting a short-term rebound is possible.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta: 1.28)
Volatility Regime: Current volatility is high compared to historical levels (HV20: 67.2%, HV30: 61.2%, HV60: 71.7%)
Options Market Signals: No options data available
Downside Protection: Support levels at $2.03 and risk management considerations are in place.
Market Context & Positioning
Sector Performance: PALI's performance is relatively strong within its sector (R-squared: 0.64)
Institutional Activity: Institutional interest signals are mixed, with some buying and selling activity observed.
Correlation Analysis: The stock moves moderately correlated to the market (correlation: 0.14)
Relative Valuation: PALI is trading near the middle of its historical range, suggesting a relatively fair valuation.
Key Levels & Action Items
Critical Price Levels: Support at $2.03 and resistance at $2.15
Breakout/Breakdown Levels: A potential breakout above $2.20 or breakdown below $1.93 could trigger significant moves
Time-Sensitive Catalysts: Upcoming investor conferences and potential product updates may impact the stock's performance.
Risk Management: Stop-loss levels and position sizing considerations are in place to manage risk.
This analysis provides a comprehensive assessment of PALI, taking into account technical indicators, recent news headlines, risk metrics, and market context. The report highlights the importance of considering both bullish and bearish cases when evaluating this stock.
Generated
News
All PALI news →
PALI Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.2257
Alpha: -8.61%
Correlation: 0.1695
R-Squared: 2.9%
Stock Volatility: 92.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PALI
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $11.0M | #733 of 1945 | +1175.8% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $2.4M | #1866 of 3138 | -22.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.1M | #2857 of 6285 | +7024.8% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.0M | #2594 of 3716 | -55.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1K | #4524 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PALI Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
PALI Insider Trading (Form 4)
Latest: 2026-10-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Julien E. Capers | See Remarks | Award (A) | +787,300 | — | EDGAR | |
| 2026-10-07 | Mitchell Lawrence Jones | See Remarks | Mixed | +1,589,748 | $1.49 | -$1.54M | EDGAR |
| 2026-10-07 | John David Finley | CEO CFO | Mixed | +1,815,402 | $1.49 | -$2.10M | EDGAR |
| 2026-10-05 | Donald Allen Williams | Director | Buy (P) | +20,000 | $1.44 | $28.8K | EDGAR |
| 2026-08-21 | John David Finley | CEO, CFO | Gift (G) | — | — | EDGAR | |
| 2026-07-10 | Robert Baltera Jr. | Director | Buy (P) | +45,000 | $1.97 | $88.7K | EDGAR |
| 2026-07-08 | Robert Baltera Jr. | Director | Buy (P) | +50,000 | $2.04 | $102.1K | EDGAR |
| 2026-07-08 | John David Finley | CEO, CFO | Mixed | +188,502 | $2.07 | -$303.3K | EDGAR |
| 2026-07-08 | Mitchell Lawrence Jones | Chief Medical Officer | Mixed | +79,287 | $2.05 | -$106.5K | EDGAR |
| 2026-07-06 | Robert Baltera Jr. | Director | Buy (P) | +30,000 | $1.98 | $59.4K | EDGAR |
| 2026-06-18 | Robert Baltera Jr. | Director | Award (A) | +336,904 | — | EDGAR | |
| 2026-06-12 | Jordan Michael Zwick | Director | Award (A) | +336,904 | — | EDGAR | |
| 2026-06-12 | Donald Allen Williams | Director | Mixed | +1,559,566 | — | EDGAR | |
| 2026-06-12 | Binxian Wei | Director | Mixed | +612,500 | — | EDGAR | |
| 2026-06-12 | Emil Chuang | Director | Mixed | +612,500 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PALI Insider Holdings
8 insiders · @ $1.23
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mitchell Lawrence Jones | See Remarks | 2,714,859 | $3.34M | -$110.0K | 12 | 2026-10-07 |
| 2 | John David Finley | CEO CFO | 2,033,141 | $2.50M | -$208.7K | 41 | 2026-10-07 |
| 3 | Donald Allen Williams | Director | 1,583,294 | $1.95M | $68.3K | 17 | 2026-10-05 |
| 4 | Julien E. Capers | See Remarks | 787,300 | $968.4K | $0 | 1 | 2026-10-21 |
| 5 | Binxian Wei | Director | 613,355 | $754.4K | $0 | 10 | 2026-06-12 |
| 6 | Emil Chuang | Director | 612,500 | $753.4K | $0 | 5 | 2026-06-12 |
| 7 | Robert Baltera Jr. | Director | 461,904 | $568.1K | $250.2K | 4 | 2026-07-10 |
| 8 | Jordan Michael Zwick | Director | 336,904 | $414.4K | $0 | 1 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PALI Board & Officers
As of SEC filings through Oct 21, 2026Directors 6
- Binxian Wei · since Feb 10, 2019
- Donald Allen Williams · since Apr 27, 2021
- John David Finley · listed since Feb 2023
- Emil Chuang · since Jul 7, 2025
- Jordan Michael Zwick · since Jun 10, 2026
- Robert Baltera Jr. · since Jun 10, 2026
Officers 3
- John David Finley · CEO, CFO · listed since Feb 2025
- Mitchell Lawrence Jones · Chief Medical Officer · since Sep 5, 2023
- Julien E. Capers · General Counsel & Corporate Secretary · since Oct 19, 2026
Changes in the last 10 years (34)
| Oct 19, 2026 | Julien E. Capers became General Counsel & Corporate Secretary |
| Jun 10, 2026 | Robert Baltera Jr. became a director |
| Jun 10, 2026 | Jordan Michael Zwick became a director |
| Jul 7, 2025 | Emil Chuang became a director |
| Jul 2, 2025 | The company announced the departure of Margery B. Fischbein from the board in an SEC filing |
| Feb 13, 2025 | John David Finley listed as CEO, CFO (previously CEO, CFO, Director) in SEC filings |
| May 7, 2024 | Margery B. Fischbein became a director |
| Mar 4, 2024 | The company announced the departure of Mary Ann Gray from the board in an SEC filing |
| Feb 13, 2024 | Stephanie Diaz reported in an SEC filing no longer being a director |
| Feb 13, 2024 | Robert J. Trenschel reported in an SEC filing no longer being a director |
| Feb 13, 2024 | James R Neal reported in an SEC filing no longer being a director |
| Feb 13, 2024 | Cristina Csimma reported in an SEC filing no longer being a director |
| Sep 5, 2023 | Mitchell Lawrence Jones became Chief Medical Officer |
| Feb 8, 2023 | John David Finley listed as CEO, CFO, Director (previously Chief Financial Officer) in SEC filings |
| Feb 8, 2023 | John David Finley first listed as a director in an SEC filing |
| Feb 2, 2023 | Robert Curtis McRae became Chief Operating Officer |
| Oct 17, 2022 | The company announced the departure of Michael John Dawson as Chief Medical Officer in an SEC filing |
| Oct 14, 2022 | The company announced the departure of Thomas Hallam from the board in an SEC filing |
| Oct 14, 2022 | The company announced the departure of Thomas Hallam as Chief Executive Officer in an SEC filing |
| Aug 19, 2021 | Regional Medical Center Yuma became a 10% owner |
| Apr 27, 2021 | Thomas Hallam became a director |
| Apr 27, 2021 | Thomas Hallam became Chief Executive Officer |
| Apr 27, 2021 | Stephanie Diaz became a director |
| Apr 27, 2021 | Robert J. Trenschel became a director |
| Apr 27, 2021 | Michael John Dawson became Chief Medical Officer |
| Apr 27, 2021 | John David Finley became Chief Financial Officer |
| Apr 27, 2021 | James R Neal became a director |
| Apr 27, 2021 | Donald Allen Williams became a director |
| Jul 19, 2019 | Mary Ann Gray became a director |
| Jun 17, 2019 | David J Mazzo became a director |
| Feb 10, 2019 | Binxian Wei became a director |
| Dec 12, 2018 | Kenneth C Carter became a director |
| Dec 12, 2018 | Kenneth C Carter became Executive Chairman |
| Sep 25, 2017 | Cristina Csimma became a director |
Not reported recently (10)
- Robert Curtis McRae · Last reported as Chief Operating Officer in an SEC filing dated Apr 5, 2023
- Regional Medical Center Yuma · Last reported as a 10% owner in an SEC filing dated Aug 26, 2021
- David J Mazzo · Last reported as a director in an SEC filing dated Apr 26, 2021
- Scott Varde Ogilvie · Last reported as a director in an SEC filing dated Oct 11, 2019
- Kenneth C Carter · Last reported as a director in an SEC filing dated Oct 11, 2019
- William Clyde Oldaker · Last reported as a director in an SEC filing dated Jul 3, 2019
- Sandford D Smith · Last reported as a director in an SEC filing dated Jul 3, 2019
- Stanley Westreich · Last reported as a director in an SEC filing dated Jul 5, 2018
- Richard J Daly · Last reported as a director in an SEC filing dated Nov 9, 2017
- Jones Jonathan Brian Lloyd · Last reported as Chief Financial Officer in an SEC filing dated Mar 27, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PALI Proposed Insider Sales (Form 144)
Latest: 2026-07-07
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | Jones Mitchell Lawrence | Officer | 53,000 | $108.1K | 2026-07-07 | Raymond James & Associates | — | EDGAR |
| 2026-07-07 | Finley John David | Officer | 146,798 | $303.3K | 2026-07-07 | Raymond James & Associates | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
21 ETFs hold PALI
21 shown · $21.60M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $8.0M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.2M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.4M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.6M | $13.9B | 2026-10-23 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.2M | — | 2026-09-30 |
| 6 | SURI Simplify Propel Opportunities ETF | Nport | 1.22% | $941,635 | — | 2026-06-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $623,137 | $1.2B | 2026-10-23 |
| 8 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $511,474 | $96.5B | 2026-10-23 |
| 9 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $330,232 | $13.7B | 2026-10-23 |
| 10 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $254,800 | $3.2B | 2026-10-23 |
| 11 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.02% | $237,664 | $1.0B | 2026-10-23 |
| 12 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $155,883 | — | 2026-09-30 |
| 13 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $88,426 | — | 2026-10-26 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $38,448 | — | 2026-09-30 |
| 15 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $16,655 | — | 2026-09-30 |
| 16 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $10,761 | — | 2026-10-26 |
| 17 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $8,252 | — | 2026-10-26 |
| 18 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $5,796 | — | 2026-10-26 |
| 19 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.01% | $418 | — | 2026-06-30 |
| 20 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $228 | — | 2026-10-26 |
| 21 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $65 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.